Anti-VEGF Treatment Leads To Better Vision Outcomes For Premature Babies
The Vision Problem For Premature Infants
Many babies born too early face a serious eye condition called retinopathy of prematurity. Doctors often treat this problem to stop the eye from growing abnormally. However, the treatments used in the past often left these children with significant nearsightedness.
This nearsightedness can make it hard for them to see clearly as they grow up. It can affect their ability to read, learn, and play without glasses. Parents often worry about this long-term side effect when choosing a treatment plan.
Doctors have several tools to fix damaged blood vessels in the eyes of premature infants. These tools include laser therapy, freezing with liquid nitrogen, and surgery. Each method works to stop the disease from spreading.
But each method also changes how the eye grows afterward. Some methods cause the eye to become too long. This leads to high levels of nearsightedness that require strong corrective lenses. Finding the right balance between saving the eye and preserving normal vision is a major challenge.
A New Twist In Treatment
But here is the twist. A new systematic review compared these different methods side by side. The study looked at data from over ten thousand eyes across eighty-six different studies.
The results were clear. The anti-VEGF injection method produced the most favorable vision outcomes. It resulted in much less nearsightedness than the other common treatments. This suggests that this newer approach might be the better choice for many patients.
How The Eye Grows After Treatment
To understand why this happens, imagine the eye as a balloon that needs to grow to the right size. When the eye grows too fast, it becomes nearsighted. This happens because the eye stretches too much.
Anti-VEGF works by stopping abnormal blood vessel growth. This allows the eye to develop more normally. Laser and freezing methods, on the other hand, can sometimes cause the eye to grow too long. This creates a traffic jam of signals that tell the eye to stretch beyond its normal limit.
The researchers analyzed data from eight hundred and sixty studies. They found that anti-VEGF resulted in a mean spherical equivalent of minus 1.9 diopters. This is a much lower level of nearsightedness than the other methods.
Laser therapy resulted in a mean of minus 3.8 diopters. Freezing methods and surgery resulted in even higher levels of nearsightedness. The risk of developing high myopia was much lower with anti-VEGF. Only about twenty-one percent of eyes treated this way developed high myopia.
This doesn't mean this treatment is available yet.
The Catch In The Data
But there is a catch. The study noted that the results varied quite a bit between different groups. Some studies showed different results than others. This variation is common in medical research.
The researchers also looked at different zones of the eye. They found that the risk of high myopia depended on where the treatment was applied. Zone I treatments had different risks than Zone II or III treatments.
What Experts Say
Experts agree that long-term vision outcomes must be part of the decision-making process. Choosing a treatment is not just about saving the eye. It is also about ensuring the child has good vision for the future.
This new data gives doctors a clearer picture of the trade-offs. It helps them explain the risks and benefits to parents. Parents can now make more informed choices about their child's care.
What This Means For Families
This research does not mean parents should demand this specific treatment immediately. It means doctors can use this information to guide their choices. Some patients may still need laser or freezing based on their specific situation.
Doctors will likely use this data to update their guidelines. They will consider the long-term vision risks when planning care. This ensures that premature babies get the best possible start in life.
The study had some limitations. The results varied between different studies. Some studies included different types of patients. This makes it hard to apply the findings to every single case.
The research also looked at data up to July 2025. New treatments and techniques may emerge soon. Future studies will need to confirm these findings in larger groups of patients.
More research is needed to confirm these results. Doctors will continue to study how these treatments affect vision over time. They will also look at combining different methods to get the best results.
This new information is a step forward for premature infants. It offers hope for better vision outcomes in the future. Parents and doctors can work together to protect the eyes of the next generation.
